BioSpace News Archive

In a landmark decision, the U.S. Food and Drug Administration has approved the first at-home oral pill, zuranolone, which will be sold under the brand named Zurzuvae, for treating perinatal or postpartum depression – a condition one in eight birthing women experience.

Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced its financial and operating results for the second quarter ended June 30, 2023 and provided a corporate update.

AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today reported operating results for the second quarter ended June 30, 2023 and provided a business update.

Medivir AB, a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announced the formation of a Scientific Advisory Council as the company intensifies its plans for next phase of development.

Annexon, Inc., a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders, highlighted recent progress across its business and portfolio of complement therapies and reported second quarter 2023 financial results.

Centogene N.V., the essential life science partner for data-driven answers in rare and neurodegenerative diseases, announced its conference schedule for August 2023.

Nektar Therapeutics announced that efficacy data previously generated by Eli Lilly & Company for rezpegaldesleukin that were presented at the September 2022 EADV Congress were incorrectly calculated by Lilly.

NRx Pharmaceuticals, Inc., a late-stage biopharmaceutical company, announced that it will release its second quarter 2023 financial results after the market closes on Monday, August 14, 2023, via press release, which will be available on the Company’s website.

Henry Schein, Inc., the world’s largest provider of health care solutions to office-based dental and medical practitioners, reported financial results for the second quarter ended July 1, 2023.

Viatris Inc., a global healthcare company, and Mapi Pharma Ltd., a fully integrated, late-stage clinical development pharmaceutical company, announced that the U.S. Food and Drug Administration has accepted for review the companies’ recently submitted New Drug Application for GA Depot 40 mg.